Table 1.
Summary of previously reported cases of prostatic stromal tumors.
| No. | Age (years) | Clinical features | Diagnostic specimen | Immunohistochemistry | Treatment | Follow-up time (months) | Outcome | Reference |
|---|---|---|---|---|---|---|---|---|
| 1 | 27 | Urinary retention, lower urinary tract symptoms, hematuria | TURP | Vimentin (+), CD34 (+), SMA (+) | TURP | 78 | Dysuria | Shen et al.6 (2021) |
| 2 | 31 | Lower urinary tract symptoms | Biopsy | SMA (±), CD34 (+), ER (±), PR (±) | None | 74 | No recurrence or metastasis | Shen et al.6 (2021) |
| 3 | 73 | Urinary retention, lower urinary tract symptoms | TURP | TURP | / | / | Shen et al.6 (2021) | |
| 4 | 67 | Urinary retention, lower urinary tract symptoms | Biopsy | Vimentin (+), SMA (+), CD34 (±), PR (±) | TURP | 68 | No recurrence or metastasis | Shen et al.6 (2021) |
| 5 | 66 | Lower urinary tract symptoms, hematuria | RP | Vimentin (+), CD34 (+), PR (+) | RP | / | / | Shen et al.6 (2021) |
| 6 | 77 | Lower urinary tract symptoms, hematuria | Biopsy | TURP | / | / | Shen et al.6 (2021) | |
| 7 | 66 | Lower urinary tract symptoms, hematuria | RP | Vimentin (+), SMA (+), CD34 (±) | RP | 57 | No recurrence or metastasis | Shen et al.6 (2021) |
| 8 | 73 | Urinary retention, lower urinary tract symptoms | TURP | TURP | 57 | No recurrence or metastasis | Shen et al.6 (2021) | |
| 9 | 81 | Urinary retention, lower urinary tract symptoms | TURP | TURP | 56 | No recurrence or metastasis | Shen et al.6 (2021) | |
| 10 | 71 | Lower urinary tract symptoms | TURP | SMA (+), CD34 (+), ER (±), PR (+) | TURP | 56 | No recurrence or metastasis | Shen et al.6 (2021) |
| 11 | 71 | Urinary retention, lower urinary tract symptoms | Biopsy | SMA (+) | None | / | / | Shen et al.6 (2021) |
| 12 | 51 | No obvious symptoms | RP | Vimentin (+), SMA (+), ER (±), PR (+) | None | 27 | No recurrence or metastasis | Shen et al.6 (2021) |
| 13 | 39 | Lower urinary tract symptoms, urinary retention | Biopsy | Vimentin (+), ER (+), PR (+) | None | 10 | No recurrence or metastasis | Shen et al.6 (2021) |
| 14 | 78 | Lower urinary tract symptoms | RP | SMA (+), CD34 (+), PR (+) | RP | / | / | Shen et al.6 (2021) |
| 15 | 58 | Lower urinary tract symptoms, urinary retention | Biopsy | None | / | / | Shen et al.6 (2021) | |
| 16 | 53 | No obvious symptoms | RP | CD34 (±), ER (±), PR (+) | RP | 86 | No recurrence or metastasis | Shen et al.6 (2021) |
| 17 | 75 | Lower urinary tract symptoms | TURP | Vimentin (+), SMA (±), CD34 (+), ER (+), PR (+) | TURP | 85 | No recurrence or metastasis | Shen et al.6 (2021) |
| 18 | 33 | Lower urinary tract symptoms, urinary retention | Biopsy | TURP | 7 | Dysuria | Shen et al.6 (2021) | |
| 19 | 37 | Hematuria, lower urinary tract symptoms | RP | CD34 (±) | RP | 16 | Recurrence and death | Shen et al.6 (2021) |
| 20 | 25 | Lower urinary tract symptoms, urinary retention | Biopsy | Vimentin (+), SMA (±), CD34 (+) | Prostatectomy | / | / | Shen et al.6 (2021) |
| 21 | 61 | Hematuria | RP | Vimentin (+), SMA (+), CD34 (+) | RP and total pelvic exenteration | 6 | Recurrence | Shen et al.6 (2021) |
| 22 | 40 | Lower urinary tract symptoms, urinary retention | TURP | Vimentin (+), SMA (±), CD34 (±) | TURP and radical cystectomy | 24 | Recurrence | Shen et al.6 (2021) |
| 23 | 23 | Lower urinary tract symptoms, urinary retention | TURP | Vimentin (+), SMA (+), CD34 (±) | TURP and radical cystectomy | / | / | Shen et al.6 (2021) |
| 24 | 29 | Urinary emptying disorder and hematuria | Biopsy | Not available | TURP+RP | 2 | No recurrence or metastasis | Syarif et al.7 (2023) |
| 25 | 53 | Left back pain and lower urinary tract symptoms | Biopsy | CD117 (+), CD34 (+), PR (+), Desmin (+), SMA (−) | RP | 12 | No recurrence or metastasis | Wang et al.8 (2014) |
| 26 | 62 | Abnormal DRE | Biopsy | Not available | None | 12 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 27 | 64 | Abnormal DRE | Biopsy | Not available | None | 34 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 28 | 67 | Abnormal DRE | Biopsy | Not available | TURP | 86 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 29 | 63 | Urinary retention | TURP | Not available | TURP | 11 | Death of other cause | Gaudin et al.9 (1998) |
| 30 | 51 | Urinary retention | SP | Vimentin (+), CD34 (+), Desmin (±), PR (+) | SP | 60 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 31 | 47 | Constipation, nocturia, palpable prostate mass | TUB | Not available | Exploratory laparotomy, partial prostatectomy and excision of mass | / | Not available | Gaudin et al.9 (1998) |
| 32 | 48 | Gross hematuria | TUB | Not available | TUB | 6.5 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 33 | 65 | Abnormal DRE | Biopsy | Not available | None | 2 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 34 | 27 | Rectal fullness, prostate mass | Biopsy | Not available | Hormones, RCP | 35 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 35 | 43 | Urinary retention, prostate mass | TURP | Vimentin (+), CD34 (±), SMA (+) | TURP | 18 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 36 | 52 | Palpable rectal mass | TURP | Vimentin (+), CD34 (+), Desmin (+), PR (±) | TURP and modified pelvic exenteration | 76 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 37 | 53 | No obvious symptoms | RP for PCa | Not available | RP | 10 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 38 | 51 | Urinary retention, hematuria | Biopsy | Vimentin (+), CD34 (+), SMA (+), Desmin (+), PR (+) | TURP | 136 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 39 | 39 | Urinary retention | TURP | Vimentin (+), CD34 (±), ER (+), PR (+) | TURP, finasteride, and RP | 71 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 40 | 65 | Urinary retention | TURP | Not available | TURP | 6 | Death of other cause | Gaudin et al.9 (1998) |
| 41 | 71 | Urinary retention, hematuria | Biopsy | Not available | RP | 0.5 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 42 | 55 | Urinary retention | TURP | Vimentin (+), CD34 (±), PR (+) | TURP+RP | 21 | No recurrence or metastasis | Gaudin et al.9 (1998) |
| 43 | 60 | Urinary retention | Biopsy | Desmin (+), CD34 (−), PR (−) | RARP | 103 | No recurrence or metastasis | Dokubo et al.12 (2023) |
| 44 | 65 | Abnormal DRE | Biopsy | Desmin (+), CD34 (−) | RARP | 57 | No recurrence or metastasis | Dokubo et al.12 (2023) |
| 45 | 64 | Mild obstructive voiding symptoms | Biopsy | Vimentin (+), Desmin (+), PR (+) | RARP | 6 | No recurrence or metastasis | Chan et al.13 (2022) |
| 46 | 71 | Mild obstructive voiding symptoms | Biopsy | Not available | RP | 17 | No recurrence or metastasis | Ladner et al.14 (2021) |
| 47 | 52 | Progressive urinary retention | Biopsy | Not available | RP | 18 | Death | Muglia et al.16 (2011) |
| 48 | 63 | No obvious symptoms | Biopsy | CD34 (+), PR (−), Desmin (+) | Not available | Not available | Not available | Johnson and Carter17(2015) |
| 49 | 67 | Urinary retention | TURP | Not available | TURP | 60 | No recurrence or metastasis | De Berardinis et al.18 (2012) |
| 50 | 53 | Febrile prostatitis, urinary retention | Biopsy | Not available | TURP | 13 | STUMP still detectable, but no signs of sarcoma | Laturnus et al.23 (2010) |
| 51 | 77 | Weak urinary stream | Biopsy | CD34 (+), Desmin (+), SMA (−) | RP | 19 | No recurrence or metastasis | Inagaki et al.24 (2015) |
| 52 | 56 | Urinary retention | Not available | Not available | TURP | Not available | Not available | Wee et al.26 (2005) |
| 53 | 56 | Urinary frequency | Biopsy | Not available | RP | 12 | No recurrence | Okada et al.28 (2013) |
| 54 | 60 | No obvious symptoms | Biopsy | CD34 (+), PR (+), SMA (+) | RARP | 6 | No recurrence or metastasis | Suzuki et al.32 (2020) |
CD117, cluster of differentiation 117; CD34, cluster of differentiation 34; DRE, digital rectal examination; ER, estrogen receptor; PCa, prostate cancer; PR, progesterone receptor; PSA, prostate-specific antigen; RARP, robot-assisted radical prostatectomy; RCP, radical cyst prostatectomy; RP, radical prostatectomy; SMA, smooth muscle actin; SP, suprapubic prostatectomy; STUMP, stromal tumors of unknown malignant potential; TUB, transurethral biopsy; TURP, transurethral resection of the prostate.